| | | |   | | | | By Ed Silverman Adobe “Real questions remain on a range of issues," said U.S. Trade Representative Katherine Tai on a waiver extension being discussed at the WTO. Read More | | By Ed Silverman Adobe “Increases in drug prices frequently occur without important new evidence,” said David Rind, ICER’s chief medical officer. Read More | | By Ed Silverman Adobe “The responsibility of the (French) regulator is flagrant," said Gérard Bapt, a medical adviser to the Association of French Thyroid Patients. Read More | | Sponsored Insight by Myriad Genetics Helping women understand their breast cancer risk with genetic testing Approximately 13% of women in the United States will develop breast cancer in their lifetime1. That's one in eight women. We have an opportunity to advance the healthcare system to one that is driven by knowing risk and getting ahead of disease before it may even happen. Let's break down barriers and increase the adoption of genetic testing across the continuum of care to improve health outcomes for patients in breast cancer — and ultimately, many other cancers. Learn more. 1. Breastcancer.org, Breast Cancer Facts and Statistics, https://www.breastcancer.org/facts-statistics | | By Adam Feuerstein Adobe The results raise concerns that the drug for pulmonary arterial hypertension may not provide a meaningful benefit for patients. Read More | | By Matthew Herper and Allison DeAngelis STAT Eisai CEO Ivan Cheung and Penn Memory Center's Jason Karlawish discussed the possible risks and benefits of the drug at a STAT event. Read More | |
No comments